Nov 13, 2020 9:00am EST Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results
Nov 05, 2020 9:00am EST Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials
Oct 28, 2020 9:00am EDT Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the Clinical Development of AS1411 as a Treatment for COVID-19
Oct 08, 2020 9:00am EDT Qualigen Therapeutics Enters into Commercialization Agreement for its FastPack® Diagnostic Products in China
Oct 01, 2020 9:00am EDT Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate
Sep 17, 2020 9:00am EDT Qualigen Therapeutics Announces Filing of U.S. Provisional Patent Application for the Use of AS1411 to Prevent Viral Infections
Aug 31, 2020 9:00am EDT Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug Product
Aug 20, 2020 8:00am EDT Qualigen Therapeutics Announces Issuance of STARS™ Technology Patent by the U.S. Patent and Trademark Office
Aug 14, 2020 5:24pm EDT Qualigen Therapeutics Announces Business Highlights and First Quarter Fiscal Year 2021 Financial Results; Has $16 Million in Cash on Hand as of Today
